Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe : Preliminary Report

Authors :: Agnandji, Selidji T
Csaki Huttner, Angela
Zinser, Madeleine E
Njuguna, Patricia
Dahlke, Christine
Fernandes, José F
Yerly, Sabine
Dayer, Julie-Anne
Kraehling, Verena
Kasonta, Rahel
Adegnika, Akim A
Altfeld, Marcus
Auderset, Floriane
Bache, Emmanuel B
Biedenkopf, Nadine
Borregaard, Saskia
Brosnahan, Jessica S
Burrow, Rebekah
Combescure, Christophe
Desmeules, Jules Alexandre
Eickmann, Markus
Fehling, Sarah K
Finckh, Axel
Goncalves Cabecinhas, Ana Rita
Grobusch, Martin P
Hooper, Jay
Jambrecina, Alen
Kabwende, Anita L
Kaya, Gurkan
Kimani, Domtila
Lell, Bertrand
Lemaître, Barbara
Lohse, Ansgar W
Massinga-Loembe, Marguerite
Matthey, Alain
Mordmüller, Benjamin
Nolting, Anne
Ogwang, Caroline
Ramharter, Michael
Schmidt-Chanasit, Jonas
Schmiedel, Stefan
Silvera, Peter
Stahl, Felix R
Staines, Henry M
Strecker, Thomas
Stubbe, Hans C
Tsofa, Benjamin
Zaki, Sherif
Fast, Patricia
Moorthy, Vasee
Kaiser, Laurent
Krishna, Sanjeev
Becker, Stephan
Kieny, Marie-Paule
Bejon, Philip
Kremsner, Peter G
Addo, Marylyn M
Siegrist, Claire-Anne
VSV Ebola Consortium (VEBCON)
Source :: New England Journal of Medicine, Vol. 374, No 17 (2016) pp. 1647-1660
Publication Year :: 2016
Abstract: The replication-competent recombinant vesicular stomatitis virus (rVSV)–based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein was selected for rapid safety and immunogenicity testing before its use in West Africa.

Language :: English
ISSN :: 00284793
Database :: OpenAIRE
Journal :: New England Journal of Medicine, Vol. 374, No 17 (2016) pp. 1647-1660
Accession number :: edsair.od......1400..b09b45039cf51bef1bf828f6d8ddd81a

Tools